Synthetic Biology Startups
33 companies tagged Synthetic Biology, with their investors and founders.
Ginkgo Bioworks builds autonomous labs and offers cell-programming and bioengineering services for the biopharma, agriculture, and industrial biotech markets. The company operates in the synthetic biology industry, developing engineered organisms and foundry technology for customers across these sectors.
21 investors
Z Biotic develops genetically engineered probiotics designed to improve daily health and wellbeing. The company uses biotechnology to create targeted probiotic products for consumers.
13 investors
Living Carbon develops precision-bred tree varieties and reforestation techniques to convert marginal land into carbon-sequestering ecosystems. The company targets climate mitigation through enhanced photosynthesis and biodiversity restoration.
12 investors
Opentrons develops laboratory robots that automate scientific research tasks for scientists and research institutions. The company aims to democratize access to laboratory automation and increase the availability of robotic systems to accelerate discovery in life sciences.
12 investors
Genecis commercializes the production of polyhydroxyalkanoate (PHA), a biodegradable polymer made from bacteria that consume organic waste, offering a sustainable alternative to petroleum-based plastics for packaging, textiles, medical devices, and other applications. The company applies circular economy principles to create high-quality, eco-friendly products that break down naturally without microplastic pollution.
7 investors
Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.
7 investors
ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
7 investors
Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.
6 investors
Ligo develops computational tools for enzyme design by combining large language models with specialized neural networks to enable scientists and AI agents to discover new enzymes and biological functions.
6 investors
Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials. The company serves protein engineers and researchers developing therapeutic and industrial biological products.
5 investors
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.
5 investors
Granza Bio develops immunotherapy treatments leveraging naturally-occurring attack particles that are released from cytotoxic immune cells to target diseases including cancers, autoimmunity, and infections.
5 investors
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.
5 investors
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
4 investors
Invert provides infrastructure and intelligence software that connects bioprocess equipment and data sources for pharmaceutical and biologics companies, enabling faster process development and manufacturing through integrated data platforms and digital twin capabilities.
4 investors
Lygos uses genetically engineered microorganisms to produce industrial chemicals from sugar feedstocks, focusing on compounds where fermentation offers cost advantages compared to fossil fuel-based manufacturing.
4 investors
1849 bio engineers microorganisms to make metal extraction from low-grade copper and gold ores economically viable for mining operations. The company applies advanced bioengineering techniques to develop microbes capable of processing ore types that existing biomining processes cannot handle, targeting the hundreds of billions of dollars in copper currently considered uneconomical to extract.
3 investors
Abalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.
3 investors
inSoma Bio develops biomaterial products for reconstruction plastic surgery, enabling surgeons to use patients' own tissue instead of synthetic implants and fillers for breast and facial reconstruction procedures.
3 investors
Synvivia engineers molecules designed to reprogram cells. The company operates in the biotech sector.
3 investors
Birch Biosciences develops enzyme-based plastic recycling technologies using green chemistry and machine learning to transform plastic waste into reusable material. The company targets the plastic resin market with solutions for industrial and commercial recycling applications.
2 investors
Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
2 investors
ACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.
1 investor
Amino Analytica designs rapid molecular diagnostic tests for emerging infectious diseases and biological threats, developed in weeks rather than the traditional 12+ months. The company combines point-of-care diagnostics technology with AI-driven bionanotechnology to enable earlier detection and faster pandemic response.
1 investor